EOSINOPHIL SURVIVAL ACTIVITY IDENTIFIED AS INTERLEUKIN-5 IS ASSOCIATED WITH EOSINOPHIL RECRUITMENT AND DEGRANULATION AND LUNG INJURY 24 HOURS AFTER SEGMENTAL ANTIGEN LUNG CHALLENGE

被引:69
作者
OHNISHI, T
SUR, S
COLLINS, DS
FISH, JE
GLEICH, GJ
PETERS, SP
机构
[1] THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV PULM MED & CRIT CARE,804 COLL BLDG,PHILADELPHIA,PA 19107
[2] MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905
[3] MAYO CLIN & MAYO FDN,DEPT MED,ROCHESTER,MN 55905
关键词
EOSINOPHILS; EOSINOPHIL SURVIVAL ACTIVITY; IL-5; IGE-MEDIATED PULMONARY INFLAMMATION; SEGMENTAL ANTIGEN CHALLENGE;
D O I
10.1016/0091-6749(93)90085-T
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Segmental antigen challenge in allergic volunteer subjects leads to the recruitment of inflammatory cells, including eosinophils, to the lung and to lung injury as shown by albumin influx into the alveolar air space. The goal of this study was to determine whether eosinophil-active cytokines, including IL-3, IL-5, or granulocyte-macrophage colony-stimulating factor, are released into the lung 24 hours after segmental antigen challenge of ragweed allergic subjects with allergic rhinitis and to determine whether the presence of the cytokine or cytokines is correlated with markers of lung inflammation and lung injury. Methods: Volunteers underwent challenge with a wide variety of antigen doses, which resulted in the recruitment of inflammatory cell mixtures both with and without eosinophils. Results: Eosinophil survival activity (ESA), the ability of the cytokine to prolong blood eosinophil survival in culture, was found in 5 of 17 ragweed allergic subjects and only in subjects challenged with relatively high doses of ragweed antigen (0.2 ragweed antigen units/ml or more). No ESA was found in bronchoalveolar lavage (BAL) fluid in any of eight nonragweed allergic subjects. This activity could be almost completely neutralized by preincubating RAL fluid with specific antibody to IL-5, although a small contribution by granulocyte-macrophage colony-stimulating factor may also have been present. ESA correlated with eosinophil recruitment (r = 0.72, p < 0.001) and degranulation in the lung (r = 0.63 to 0.81, p < 0.01, for eosinophil granule constituents in BAL fluid) and lung injury as shown by albumin influx into the alveolar air spaces (r = 0.83, p < 0.001). ESA was unrelated to the presence of other inflammatory cells in the lung. Subjects who had IL-5 in BAL fluid appeared to undergo more severe initial reactions to antigen challenge. Conclusions: We conclude that IL-5 is the most important constituent in ESA in the lung 24 hours after antigen challenge and that it correlates with eosinophil recruitment, degranulation, and lung injury.
引用
收藏
页码:607 / 615
页数:9
相关论文
共 41 条
[31]  
ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311
[32]   HUMAN EOSINOPHILS HAVE PROLONGED SURVIVAL, ENHANCED FUNCTIONAL-PROPERTIES, AND BECOME HYPODENSE WHEN EXPOSED TO HUMAN INTERLEUKIN-3 [J].
ROTHENBERG, ME ;
OWEN, WF ;
SILBERSTEIN, DS ;
WOODS, J ;
SOBERMAN, RJ ;
AUSTEN, KF ;
STEVENS, RL .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (06) :1986-1992
[33]   MEMBRANE PROPERTIES OF LIVING MAMMALIAN CELLS AS STUDIED BY ENZYMATIC HYDROLYSIS OF FLUOROGENIC ESTERS [J].
ROTMAN, B ;
PAPERMASTER, BW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1966, 55 (01) :134-+
[34]   SELECTIVE DIFFERENTIATION AND PROLIFERATION OF HEMATOPOIETIC-CELLS INDUCED BY RECOMBINANT HUMAN INTERLEUKINS [J].
SAITO, H ;
HATAKE, K ;
DVORAK, AM ;
LEIFERMAN, KM ;
DONNENBERG, AD ;
ARAI, N ;
ISHIZAKA, K ;
ISHIZAKA, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (07) :2288-2292
[35]   IMMEDIATE AND LATE AIRWAY RESPONSE OF ALLERGIC RHINITIS PATIENTS TO SEGMENTAL ANTIGEN CHALLENGE - CHARACTERIZATION OF EOSINOPHIL AND MAST-CELL MEDIATORS [J].
SEDGWICK, JB ;
CALHOUN, WJ ;
GLEICH, GJ ;
KITA, H ;
ABRAMS, JS ;
SCHWARTZ, LB ;
VOLOVITZ, B ;
BENYAAKOV, M ;
BUSSE, WW .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (06) :1274-1281
[36]  
SILBERSTEIN DS, 1986, J IMMUNOL, V137, P329
[37]  
TAKAFUJI S, 1991, J IMMUNOL, V147, P3855
[38]  
WALLEN N, 1991, J IMMUNOL, V147, P3490
[39]  
WALSH GM, 1990, IMMUNOLOGY, V71, P258
[40]  
WLAKER C, 1992, AM J REV RESPIR DIS, V146, P109